

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

_____, Individually and on Behalf of All
Others Similarly Situated,

Plaintiff,

v.

SPECTRUM PHARMACEUTICALS, INC.,
JOSEPH W. TURGEON, KURT A.
GUSTAFSON, and FRANCOIS LABEL,

Defendants.

CLASS ACTION COMPLAINT

JURY TRIAL DEMANDED

Plaintiff _____ (“Plaintiff”), individually and on behalf of all others similarly situated, by Plaintiff’s undersigned attorneys, for Plaintiff’s complaint against Defendants, alleges the following based upon personal knowledge as to Plaintiff and Plaintiff’s own acts, and information and belief as to all other matters, based upon, *inter alia*, the investigation conducted by and through Plaintiff’s attorneys, which included, among other things, a review of the Defendants’ public documents, conference calls and announcements made by Defendants, United States (“U.S.”) Securities and Exchange Commission

1 (“SEC”) filings, wire and press releases published by and regarding Spectrum Pharmaceuticals, Inc.
2 (“Spectrum” or the “Company”), analysts’ reports and advisories about the Company, and information
3 readily obtainable on the Internet. Plaintiff believes that substantial additional evidentiary support will
4 exist for the allegations set forth herein after a reasonable opportunity for discovery.

5 **NATURE OF THE ACTION**

6
7 1. This is a federal securities class action on behalf of a class consisting of all persons and
8 entities other than Defendants that purchased or otherwise acquired Spectrum securities between
9 December 27, 2018 and August 5, 2021, both dates inclusive (the “Class Period”), seeking to recover
10 damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under
11 Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5
12 promulgated thereunder, against the Company and certain of its top officials.

13
14 2. Spectrum is a biopharmaceutical company that develops and commercializes oncology
15 and hematology drug products. The Company’s products under development include, among others,
16 ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for
17 chemotherapy-induced neutropenia.

18
19 3. In December 2018, Spectrum submitted a Biologics License Application (“BLA”) to the
20 U.S. Food and Drug Administration (“FDA”) for ROLONTIS as a treatment for chemotherapy-induced
21 neutropenia (the “ROLONTIS BLA”).

22
23 4. Throughout the Class Period, Defendants made materially false and misleading statements
24 regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made
25 false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS manufacturing
26 facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the
27 likelihood that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum had
28

1 therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the
2 Company's public statements were materially false and misleading at all relevant times.

3 5. On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL")
4 from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and
5 indicated that a reinspection of the Company's manufacturing facility will be necessary.

6 6. On this news, Spectrum's stock price fell \$0.70 per share, or 21.54%, to close at \$2.55 per
7 share on August 6, 2021.

8 7. As a result of Defendants' wrongful acts and omissions, and the precipitous decline in the
9 market value of the Company's securities, Plaintiff and other Class members have suffered significant
10 losses and damages.
11

12 **JURISDICTION AND VENUE**

13 8. The claims asserted herein arise under and pursuant to Sections 10(b) and 20(a) of the
14 Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder by the SEC (17
15 C.F.R. § 240.10b-5).
16

17 9. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §
18 1331 and Section 27 of the Exchange Act.
19

20 10. Venue is proper in this Judicial District pursuant to Section 27 of the Exchange Act (15
21 U.S.C. § 78aa) and 28 U.S.C. § 1391(b). Spectrum is headquartered in this Judicial District, Defendants
22 conduct business in this Judicial District, and a significant portion of Defendants' actions took place
23 within this Judicial District.

24 11. In connection with the acts alleged in this complaint, Defendants, directly or indirectly,
25 used the means and instrumentalities of interstate commerce, including, but not limited to, the mails,
26 interstate telephone communications, and the facilities of the national securities markets.
27
28

PARTIES

1
2 12. Plaintiff, as set forth in the attached Certification, acquired Spectrum securities at
3 artificially inflated prices during the Class Period and was damaged upon the revelation of the alleged
4 corrective disclosures.

5 13. Defendant Spectrum is a Delaware corporation with principal executive offices located at
6 11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052. Spectrum’s common stock trades
7 in an efficient market on the NASDAQ Global Select Market (“NASDAQ”) under the ticker symbol
8 “SPPI.”
9

10 14. Defendant Joseph W. Turgeon (“Turgeon”) has served as Spectrum’s Chief Executive
11 Officer and President at all relevant times.

12 15. Defendant Kurt A. Gustafson (“Gustafson”) has served as Spectrum’s Executive Vice
13 President and Chief Financial Officer at all relevant times.
14

15 16. Defendant Francois Lebel (“Lebel”) has served as Spectrum’s Chief Medical Officer at
16 all relevant times.

17 17. Defendants Turgeon, Gustafson, and Lebel are sometimes referred to herein as the
18 “Individual Defendants.”
19

20 18. The Individual Defendants possessed the power and authority to control the contents of
21 Spectrum’s SEC filings, press releases, and other market communications. The Individual Defendants
22 were provided with copies of Spectrum’s SEC filings and press releases alleged herein to be misleading
23 prior to or shortly after their issuance and had the ability and opportunity to prevent their issuance or to
24 cause them to be corrected. Because of their positions with Spectrum, and their access to material
25 information available to them but not to the public, the Individual Defendants knew that the adverse facts
26 specified herein had not been disclosed to and were being concealed from the public, and that the positive
27
28

1 representations being made were then materially false and misleading. The Individual Defendants are
2 liable for the false statements and omissions pleaded herein.

3 19. Spectrum and the Individual Defendants are collectively referred to herein as
4 “Defendants.”

5 **SUBSTANTIVE ALLEGATIONS**

6 **Background**

7
8 20. Spectrum is a biopharmaceutical company that develops and commercializes oncology
9 and hematology drug products. The Company’s products under development include, among others,
10 ROLONTIS (eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for
11 chemotherapy-induced neutropenia.

12 **Materially False and Misleading Statements Issued During the Class Period**

13
14 21. The Class Period begins on December 27, 2018, when Spectrum issued a press release,
15 during pre-market hours, announcing its submission of the ROLONTIS BLA with the FDA. That press
16 release stated, in relevant part:

17 “ROLONTIS is an important and significant future growth driver for our
18 company,” said Joe Turgeon, President and CEO of Spectrum
19 Pharmaceuticals. “Today’s milestone brings us one step closer to bringing
20 the first novel G-CSF to healthcare providers in over 15 years in a large
21 market that is familiar to Spectrum.”

22 The BLA for ROLONTIS is supported by data from two identically
23 designed Phase 3 clinical trials, ADVANCE and RECOVER, which
24 evaluated the safety and efficacy of ROLONTIS in 643 early-stage breast
25 cancer patients for the treatment of neutropenia due to myelosuppressive
26 cytotoxic chemotherapy. The study ADVANCE was conducted under a
27 special protocol assessment (SPA) with the Agency. In both studies,
28 ROLONTIS demonstrated the pre-specified hypothesis of non-inferiority
(NI) in Duration of Severe Neutropenia (DSN) and a similar safety profile
to pegfilgrastim. ROLONTIS also demonstrated non-inferiority to
pegfilgrastim in the DSN across all 4 cycles (all NI $p < 0.0001$) in both
studies.

1 22. On February 28, 2019, Spectrum filed an Annual Report on Form 10-K with the SEC,
2 reporting the Company’s financial and operating results for the year ended December 31, 2018 (the “2018
3 10-K”). The 2018 10-K stated, in relevant part:

4 In December 2015, we reached agreement with the FDA regarding our
5 Phase 3 Special Protocol Assessment, or SPA, for ROLONTIS. This pivotal
6 Phase 3 study (ADVANCE Study, or SPI-GCF-301) was initiated in the
7 first quarter of 2016 to evaluate ROLONTIS as a treatment for
8 chemotherapy-induced neutropenia. We announced in February 2018 that
9 the top line results of this study met the non-inferiority of ROLONTIS to
10 pegfilgrastim endpoint in the Duration of Severe Neutropenia, or DSN,
across all four cycles (all $p < 0.0001$). We initiated a second pivotal Phase 3
study (RECOVER Study, or SPI-GCF-302) and announced in June 2018,
that it had also met its primary efficacy endpoint of non-inferiority in DSN
between ROLONTIS and pegfilgrastim.

11 We submitted our Biologics License Application (“BLA”) with the FDA in
12 late December 2018. Due to the recent federal government shutdown, the
13 BLA was officially received by the FDA on January 28, 2019. Once this
14 BLA is accepted by the FDA, our Prescription Drug User Fee Act date is
expected to be set for 10 months thereafter.

15 23. Appended to the 2018 10-K as exhibits were signed certifications pursuant to the
16 Sarbanes-Oxley Act of 2002 (“SOX”) by Defendants Turgeon and Gustafson, attesting that “the
17 information contained in the [2018 10-K] fairly presents, in all material respects, the financial condition
18 and results of operations of the Company.”

19 24. In connection with the 2018 10-K, Spectrum issued a press release entitled, “Spectrum
20 Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline
21 Update.” The press release stated, in relevant part:

22 “2018 was a very productive year for Spectrum in which our two promising
23 pipeline products significantly progressed in clinical development,” said
24 Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We begin
25 2019 with great momentum after meeting the enrollment target for the first
26 cohort in our pivotal poziotinib study and submitting the BLA for
27 ROLONTIS to the FDA at the end of 2018. In 2019, we are laser-focused
28 on continuing to develop our two late-stage products, poziotinib and
ROLONTIS, and looking for new opportunities that build upon these
assets.”

1 was required before March 29, 2019, the day that the FDA’s initial 60-day
2 review period ends.

3 “We are continuing to have productive discussions with the FDA and will
4 deliver the additional information needed to support the application,” said
5 Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “We remain
6 confident in the ROLONTIS program and look forward to a successful
7 resubmission and its ultimate approval.”

8 27. On May 9, 2019, Spectrum hosted an earnings call with investors and analysts to discuss
9 the Company’s Q1 2019 results (the “Q1 2019 Earnings Call”). During the scripted portion of the Q1
10 2019 Earnings Call, Defendant Turgeon stated, in relevant part, “[w]e also continue to advance the
11 development of our late stage assets poziotinib and ROLONTIS, the cornerstones of our Company,” and
12 “[r]egarding ROLONTIS, we continue to have productive discussions with the FDA and plan to meet
13 with the agency in the near term. We are being thorough and deliberate in our updating our file, do we
14 hope it happen to the FDA as soon as it’s ready. We look forward to a successful submission and it’s
15 optimal approval.”

16 28. On August 8, 2019, Spectrum issued a press release announcing the Company’s Q2 2019
17 financial results and pipeline update. The press release stated, in relevant part:

18 “We’ve made significant progress on our pipeline in the last few months,”
19 said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. “Most
20 notably, we completed enrollment in our first two poziotinib cohorts in the
21 ZENITH20 study and expect to see results from cohort 1 in the fourth
22 quarter. Based on strong science, we’ve expanded the poziotinib
23 development program to include additional areas of high unmet medical
24 need in lung cancer. We also had a productive meeting with the FDA and
25 expect to submit the ROLONTIS BLA in the fourth quarter.”

26 ***

27 **ROLONTIS® (eflapegrastim), a novel long-acting GCSF:**

- 28 • Integrated data from both Phase 3 ROLONTIS clinical trials with 643 patients were presented in a poster session at American Society of Clinical Oncology 2019 annual meeting.
 - The analysis found that integrated efficacy and safety data from the two identically designed Phase 3 trials - ADVANCE and

1 RECOVER - were consistent with results from the individual
2 trials, demonstrating that ROLONTIS was non-inferior to
3 pegfilgrastim in the reduction of duration of severe neutropenia
4 (DSN) in all four cycles of treatment.

- 5 • Spectrum met with the FDA and expects to submit the ROLONTIS
6 BLA in the fourth quarter of 2019.

7 29. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
8 the Company's Q2 2019 results (the "Q2 2019 Earnings Call"). During the scripted portion of the Q2
9 2019 Earnings Call, Defendant Turgeon stated, in relevant part:

10 Regarding ROLONTIS, our late stage asset to use in chemotherapy-induced
11 neutropenia, we recently had a productive meeting with the FDA and plan
12 to submit the BLA in the fourth quarter. I want to remind you that we have
13 very strong efficacy and safety data coming out of two large Phase III trials.
14 If approved, this product will compete in a multibillion dollar market that I
15 and many members of our management team have a deep expertise in. We
16 look forward to successful submission and its ultimate approval.

17 Also during the scripted portion of the Q2 2019 Earnings call, Defendant Lebel stated, in relevant part:

18 Now, shifting to ROLONTIS, at ASCO, we presented a poster integrating
19 the data from both of our pivotal phase three ROLONTIS clinical trials,
20 which included a total of 643 patients. The integrated analysis of efficiency
21 and safety was consistent with results from the individual studies
22 demonstrating that ROLONTIS was non-inferior to pegfilgrastim in the
23 reduction of duration of severe neutropenia. Regarding our BLA file, we
24 recently had a productive meeting with the FDA to further discuss their
25 expectation around module three, which is the module focused on
26 manufacturing. Based on the outcome of that meeting, we expect to submit
27 the BLA in the fourth quarter of this year.

28 Finally, in answering a question regarding the "gating factors remaining prior to submitting the
[ROLONTIS] BLA," Defendant Turgeon replied, in relevant part, "[l]isten, we are aligned with the
FDA. We had our meeting, we got aligned. We're being thorough, we're being deliberate and we're
going to filing in the fourth quarter as we said. The questions that we had answered, we're in module
three, which is in the SCMC section only. And again, we're being like I said, thorough and deliberate
and plan on filing this in the fourth quarter."

1 30. On October 24, 2019, Spectrum issued a press release announcing its submission of an
2 updated ROLONTIS BLA with the FDA. That press release touted, among other things:

3 The BLA for ROLONTIS is supported by data from two identically
4 designed Phase 3 clinical trials, ADVANCE and RECOVER, which
5 evaluated the safety and efficacy of ROLONTIS in 643 early-stage breast
6 cancer patients for the treatment of neutropenia due to myelosuppressive
7 chemotherapy. In both studies, ROLONTIS demonstrated the pre-specified
8 hypothesis of non-inferiority (NI) in Duration of Severe Neutropenia (DSN)
9 and a similar safety profile to pegfilgrastim. ROLONTIS also demonstrated
10 non-inferiority to pegfilgrastim in the DSN across all 4 cycles (all NI
11 $p < 0.0001$) in both studies.

12 “We have submitted a robust package to the FDA that incorporates strong
13 clinical data and addresses previously communicated FDA requests relating
14 to manufacturing processes,” said Joe Turgeon, President and CEO of
15 Spectrum. “ROLONTIS could be the first novel G-CSF available to
16 healthcare providers in over 15 years and, if approved, we are looking
17 forward to competing in this multibillion-dollar market.”

18 In March 2019, Spectrum voluntarily withdrew the ROLONTIS BLA that
19 it filed with the FDA in 2018. The updated BLA filed today includes
20 additional information in the Chemistry, Manufacturing and Controls
21 (CMC) section.

22 31. On November 7, 2019, Spectrum issued a press release announcing the Company’s Q3
23 2019 financial results and pipeline update. The press release stated, in relevant part:

24 “Spectrum has an expanding pipeline, significant near-term milestones,
25 solid capitalization and a highly focused team,” said Joe Turgeon, President
26 and CEO, Spectrum Pharmaceuticals. “In December, we look forward to
27 results from Cohort 1 of our ZENITH20 study investigating poziotinib in
28 lung cancer patients with hard-to-treat mutations. We recently submitted
our BLA for ROLONTIS to the FDA, a key milestone, as we continue to
execute on our strategic priorities.”

29 32. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
30 the Company’s Q3 2019 results (the “Q3 2019 Earnings Call”). During the scripted portion of the Q3
31 2019 Earnings Call, Defendant Turgeon stated, in relevant part, “ROLONTIS is our late-stage drug being
32 developed for the treatment of chemotherapy-induced neutropenia. As you recall, we voluntarily
33 withdrew our BLA application earlier this year. Since then, we worked closely with the FDA and recently

1 submitted a robust package. We look forward to competing in this market.” Also during the scripted
2 portion of the Q3 2019 Earnings Call, Defendant Lebel stated, in relevant part:

3 Now shifting to ROLONTIS. ROLONTIS is a novel long-acting GCSF
4 seeking an indication for the treatment of neutropenia in patient receiving
5 myelosuppressive cancer therapy. On October 24, we submitted an
6 expanded BLA to the FDA. The withdrawal 7 months ago was driven by
7 Module 3 or the CMC section. Since then, we’ve had productive dialogue
8 with the FDA. We implemented their guidance, provided additional data
9 and rewrote and reorganized certain sections of the file resulting in a strong
10 submission.

11 As a reminder, our BLA is based on robust clinical data from 2 large pivotal,
12 independent, randomized controlled trials. In both studies, ROLONTIS met
13 the pre-specified end point of non-inferiority in duration of severe
14 neutropenia and met all secondary end points. The safety profile was similar
15 to pegfilgrastim.

16 33. On December 26, 2019, Spectrum issued a press release providing a pipeline update on
17 the Company’s late stage programs. The press release stated, in relevant part:

18 The company also announced today that the FDA has accepted for review
19 the BLA for ROLONTIS for the treatment of chemotherapy-induced
20 neutropenia. The [Prescription Drug User Fee Act] target action date for the
21 ROLONTIS BLA has been set for October 24, 2020.

22 “If approved, ROLONTIS could be the first novel granulocyte colony-
23 stimulating factor (G-CSF) available to healthcare providers in over 15
24 years,” said Joe Turgeon. “We have confidence in the future of ROLONTIS
25 and are looking forward to potentially competing in this multibillion-dollar
26 market.”

27 The BLA for ROLONTIS is supported by data from two successful large
28 pivotal Phase 3 clinical trials, ADVANCE (conducted under a SPA) and
RECOVER. These trials evaluated the safety and efficacy of ROLONTIS
in a total of 643 early-stage breast cancer patients for the treatment of
neutropenia due to myelosuppressive chemotherapy. In both trials,
ROLONTIS demonstrated the pre-specified hypothesis of non-inferiority
(NI) in duration of severe neutropenia (DSN) and a similar safety profile to
pegfilgrastim. ROLONTIS also demonstrated non-inferiority (NI) to
pegfilgrastim in the DSN across all 4 cycles of chemotherapy (all NI
p<0.0001) in both trials.

1 34. On February 27, 2020, Spectrum issued a press release announcing the Company's Q4
2 and full year 2019 financial results and pipeline update. The press release stated, in relevant part:

3 ROLONTIS is in active review by the FDA and we are preparing to launch
4 shortly following approval," said Joe Turgeon, President and CEO,
5 Spectrum Pharmaceuticals. "We believe this market represents a significant
6 commercial opportunity and our prelaunch activities are well underway. We
7 have a podium presentation on poziotinib in a few short weeks, we have
8 taken steps to adjust our strategy and we have multiple data catalysts in
9 2020. I look forward to updating you on our progress throughout the year."

10 35. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
11 the Company's Q4 and full year 2019 results (the "Q4 2019 Earnings Call"). During the scripted portion
12 of the Q4 2019 Earnings Call, Defendant Turgeon stated, in relevant part:

13 ROLONTIS is our late stage drug being developed for the treatment of
14 chemotherapy-induced neutropenia. We submitted our BLA in October of
15 2019 and it was accepted for filing with the PDUFA date of October 22,
16 2020. If approved, ROLONTIS could be the first novel granulocyte-colony
17 stimulating factor available to healthcare providers in over 15 years. We
18 have confidence in the future of ROLONTIS and are looking forward to
19 potentially competing in this multibillion dollar market.

20 36. On March 2, 2020, Spectrum filed an Annual Report on Form 10-K with the SEC,
21 reporting the Company's financial and operating results for the year ended December 31, 2019 (the "2019
22 10-K"). The 2019 10-K listed as one of the Company's recent highlights of its business:

23 **ROLONTIS, a novel long-acting G-CSF:**

24 We submitted our updated BLA for ROLONTIS with the FDA on October
25 24, 2019 due to the FDA's request for additional information in the
26 Chemistry, Manufacturing, and Controls section. The updated BLA was
27 accepted by the FDA for review on December 20, 2019. Our BLA is
28 supported by data from two identically designed Phase 3 clinical trials,
ADVANCE and RECOVER, which evaluated the safety and efficacy of
ROLONTIS in 643 early-stage breast cancer patients for the treatment of
neutropenia due to myelosuppressive chemotherapy. Our PDUFA date for
the potential approval of ROLONTIS by the FDA has been set for October
24, 2020.

In October 2019, integrated results from ADVANCE and RECOVER were
presented during a poster session at the 2019 Meeting of the American

1 Society of Clinical Oncology (ASCO) Symposium in San Francisco. The
2 integrated efficacy and safety data from both trials were consistent with
3 results from the individual trials, demonstrating that ROLONTIS was non-
4 inferior to pegfilgrastim in the reduction of duration of severe neutropenia
5 in all four cycles of treatment. The integrated data also demonstrated that
6 eflapegrastim provided an absolute risk reduction of severe neutropenia of
7 6.5% compared to pegfilgrastim in Cycle 1.

8 37. Appended to the 2019 10-K as exhibits were signed certifications pursuant to SOX by
9 Defendants Turgeon and Gustafson, attesting that “the information contained in the [2019 10-K] fairly
10 presents, in all material respects, the financial condition and results of operations of the Company.”

11 38. On April 30, 2020, Spectrum issued a press release entitled, “Spectrum Pharmaceuticals
12 Initiates Same Day Dosing Clinical Trial for ROLONTIS® (eflapegrastim).” The press release stated, in
13 relevant part:

14 Spectrum [. . .] today announced dosing of the first patient in a clinical trial
15 to evaluate the administration of ROLONTIS on the same day as
16 chemotherapy. The trial will evaluate the duration of severe neutropenia
17 when administered at three different time points on the same day following
18 standard chemotherapy in patients with early stage breast cancer.
19 ROLONTIS is an investigational drug not approved by the U.S. Food and
20 Drug Administration (FDA) and the BLA is currently under active review
21 by the agency for the treatment of chemotherapy induced neutropenia with
22 a PDUFA date of October 24, 2020.

23 “This study exemplifies our commitment to unlocking the full potential of
24 ROLONTIS, the first novel biologic positioned to enter the G-CSF market
25 since 2001. A same day dosing option would be a unique and meaningful
26 addition to the G-CSF category,” said Joe Turgeon, President and CEO of
27 Spectrum Pharmaceuticals. “We will continue to follow the science and
28 explore ways to add value to patients and health care providers. The
initiation of this study, despite the pandemic, highlights investigator’s
interest and our team’s dedication.”

39. On May 7, 2020, Spectrum issued a press release announcing the Company’s Q1 2020
financial results and pipeline update. The press release stated, in relevant part:

“The progress in our development pipeline speaks to the investigator
interest and the commitment of our team during these unprecedented
times,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals.
“The PDUFA date for ROLONTIS remains October 24, 2020 and our

1 updated poziotinib strategy is well under way. We continue to drive the
2 business forward and remain focused on achieving our milestones this
year.”

3 40. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
4 the Company’s Q1 2020 results (the “Q1 2020 Earnings Call”). During the scripted portion of the Q1
5 2020 Earnings Call, Defendant Turgeon stated, in relevant part:

6 ROLONTIS is our late-stage drug product candidate that’s currently under
7 active review at the FDA for the treatment of chemotherapy-induced
8 neutropenia with a PDUFA date of October 24, 2020. If approved,
9 ROLONTIS could be the first novel granulocyte-colony stimulating factor
10 available to healthcare providers in over 15 years. Our launch preparations
11 for ROLONTIS are actively underway. As the PDUFA date approaches we
have already put key leadership personnel in place and will accelerate our
commercial build out as we approach the launch date.

12 We’re planning to launch with a lean and effective commercial
13 infrastructure to maximize the impact of ROLONTIS. We’re closely
14 monitoring the evolving market dynamics and believe that launching this
15 novel asset will benefit patients, our customers and our shareholders. We’re
looking forward to its potential approval into competing in this multi-billion
dollar growth factor market.

16 Additionally, when asked about the likelihood of the ROLANTIS Phase 3 clinical trials being accepted
17 by the FDA, Defendant Turgeon responded, in relevant part:

18 The two trials we have, number one, there are over 600 patients - 643
19 patients as I recall - to Phase 3. This is under a SPA, which is a special
20 protocol assessment and what that means, George, is that we worked with
21 the agency, the FDA to develop the actual protocol, which they agreed. We
22 were in tandem with them. They agreed with the protocol. If you have seen
23 the data on both separate Phase 3 or in a presentation of combining the two
24 trials together, the results were outstanding. We hit all our primary and
25 secondary endpoints. Actually, it’s what’s called a non-inferiority trial. In
other words, all we had to demonstrate is we were non-inferior to the
standard of care which is the drug that’s on the market today, and we
certainly did that. You can argue in the first cycle, we actually showed some
superiority although it’s a non-inferiority trial.

26 So we feel really good about the data that we’ve submitted. All I can tell
27 you, it’s under active review as we speak. The PDUFA date, which means
28 the date of approval is October 24. That still stands despite the pandemic.

1 We're on active review and active work with the agency, so we're hoping
2 that we can get an approval this year.

3 41. On August 10, 2020, Spectrum issued a press release announcing the Company's Q2 2020
4 financial results and corporate update. The press release stated, in relevant part:

5 "The recently announced positive results from Cohort 2 are a meaningful
6 development for patients with NSCLC HER2 exon 20 insertion mutations
7 for which there is no approved therapy," said Joe Turgeon, President and
8 CEO, Spectrum Pharmaceuticals. "We are in the process of requesting a
9 pre-NDA meeting with the FDA and look forward to reviewing this data
10 with the agency. In addition, the BLA for ROLONTIS is under active FDA
11 review with a PDUFA date of October 24, 2020. We are in a strong capital
12 position to fund our ongoing development and commercialization of our late
13 stage assets."

14 42. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
15 the Company's Q2 2020 results (the "Q2 2020 Earnings Call"). During the scripted portion of the Q2
16 2020 Earnings Call, Defendant Turgeon stated, in relevant part:

17 ROLONTIS our most advanced program is under active review at the FDA
18 for the treatment of chemotherapy-induced neutropenia with a PDUFA date
19 of October 24, 2020. If approved, ROLONTIS could be the first novel
20 granulocyte-colony stimulating factor available to healthcare providers in
21 over 15 years.

22 As the PDUFA date approaches, our launch preparations for ROLONTIS
23 are accelerating. I look forward to getting back into this market, an area I
24 know well personally, and the potential of competing in this multi-billion
25 dollar growth factor market.

26 ***

27 I think you can see from everyone's remarks that Spectrum continues to
28 make outstanding progress on our pipeline and our commercial build-out in
anticipation of potential approval and launch for ROLONTIS.

43. On October 26, 2020, Spectrum issued a press release announcing that the FDA was
deferring its action on the ROLONTIS BLA. The press release stated, in relevant part:

Spectrum [. . .] today announced that an inspection of the Hanmi Bioplant
in South Korea is required before the FDA can approve the company's
Biologics License Application (BLA) for ROLONTIS. The FDA was

1 unable to conduct an inspection during the current review cycle due to
2 restrictions on travel related to the COVID-19 pandemic. Therefore, the
3 FDA is deferring action on the application until an inspection can be
4 completed. The company will continue to work actively with the FDA to
5 define an approach for scheduling the required inspection. Spectrum has
6 confirmed with the FDA that this is not a Complete Response Letter.

7 “We are actively working with the FDA to find a way to expedite the plant
8 inspection,” said Joe Turgeon, President and CEO, Spectrum
9 Pharmaceuticals. “The manufacturing facility is ready for inspection and we
10 are eager to assist the FDA in completing their assessment as soon as
11 possible.”

12 44. On November 4, 2020, Spectrum issued a press release announcing the Company’s Q3
13 2020 financial results and corporate update. The press release stated, in relevant part:

14 “The third quarter was marked by significant progress in our drug
15 development programs and a strengthened financial position,” said Joe
16 Turgeon, President and CEO, Spectrum Pharmaceuticals. “Our team is
17 preparing for the upcoming pre-NDA meeting with the FDA for poziotinib
18 and actively working to obtain an approval for ROLONTIS as soon as
19 possible.”

20 ***

21 ***ROLONTIS (eflapegrastim), a novel long-acting G-CSF***

22 The FDA deferred its action on the BLA for ROLONTIS, due to an inability
23 to inspect the Hanmi Bioplant in South Korea citing travel restrictions
24 related to the COVID-19 pandemic.
25 Spectrum has confirmed with the FDA that the deferral is not a Complete
26 Response Letter (CRL). The company is actively working to find a way to
27 expedite the plant inspection.

28 45. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
the Company’s Q3 2020 results (the “Q3 2020 Earnings Call”). During the scripted portion of the Q3
2020 Earnings Call, Defendant Turgeon stated, in relevant part:

We have answered all the inquiries from the FDA, and we’re not aware of
any outstanding items other than the inspection. We will be prudent with
our financial resources and have gated certain activities pending further
feedback or action from the FDA. Regarding the ROLONTIS plant
inspection, our partner Hanmi Pharmaceuticals is a well-established global
biopharmaceutical player with a world-class manufacturing facility.

1 Hanmi is the second largest pharmaceutical company in Korea, behind only
2 Samsung. They're prepared for the inspection and willing to be
3 accommodative to the needs of the FDA as it strives to meet the regulatory
4 obligations. They've been a great partner and are working in tandem with
5 Spectrum to obtain an approval for ROLONTIS as soon as it is possible.
6 I'm real confident in our ability to meet our corporate objectives in advance
7 of programs with the aspiration of bringing new treatments to the patients
8 with cancer, who needed it.

7 Further, when asked a question regarding mock inspections of the ROLANTIS manufacturing facility,

8 Defendant Lebel responded, in relevant part:

9 So, as we've indicated in my remark, and [Defendant Turgeon's], the – look
10 to our knowledge, right, we have received during the review of this file
11 many questions, we believe that we've answered all of them. And that the
12 FDA was satisfied. But of course, we don't know that until, you know, they
13 approved this drug. To our knowledge, the only thing outstanding right now,
14 is the inspection of our manufacturing, a main manufacturing plant.

13 In response to that same question, Defendant Turgeon stated, in relevant part:

14 And I want to stress another thing, we are absolutely ready for this
15 inspection. We are ready for a long time, we welcome it. Matter of fact, the
16 third part of your question was the mock inspections, was it required?
17 They're certainly not required by the agency. We do that to make sure we're
18 ready. And I can tell you, we have Spectrum boots on the ground there, we
19 have Hanmi, which I mentioned, is a world-class manufacturer with a
20 world-class plant. Their people are ready, and we work very closely with
21 them with these mock inspections.

20 And we have a third leg to the stool, we have outside experts, we've hired
21 to run these, not only run these mock inspections, but also help the
22 readiness. And these are people who have done this for a living. They do
23 this – they know exactly what the FDA is looking for in an inspection. So,
24 we feel we're ready. We welcome the inspection already, you know, we
25 can't wait.

24 Finally, when asked what the “cadence of discussions with the FDA” was at that moment, Defendant

25 Turgeon responded, in relevant part:

26 They have the authority to do things. So, you know, like in anything else,
27 you contact the agency, they have so much time to get back to you. Kind of
28 that's all laid out. And then we you know, we certainly can have discussions
on what's next, how can we work with you, we're willing to do whatever it

1 takes. As [Defendant Lebel] said, just yesterday, they issued, you can see
2 movement on their part for the first time in this because this is new to them.
3 And they issued the statement on moving forward. Europe's doing it, as you
4 heard already.

5 So I think they're going to have to just start moving forward. And all I'll
6 tell you is, we will do anything we can to, I'll use the word nudge them.
7 You know, you have to do it properly, but we every right to talk to them,
8 we're ready to go and try and figure out how to do this as quickly as
9 possible.

10 46. On March 16, 2021, Spectrum issued a press release providing an update on the
11 ROLONTIS pre-approval inspection. The press release stated, in relevant part:

12 Spectrum [. . .] today announced that the U.S. Food and Drug
13 Administration (FDA) has scheduled the pre-approval inspection at the
14 ROLONTIS® (eflapegrastim) manufacturing site in May 2021. In October
15 2020, the company received notification from the agency that it would defer
16 its decision on the BLA because an inspection of the Hanmi Bioplant in
17 South Korea could not be conducted during the review cycle due to
18 restrictions on travel related to the COVID-19 pandemic.

19 "I am thrilled that the FDA informed us that they will be conducting a pre-
20 approval inspection of the ROLONTIS manufacturing facility in May," said
21 Joe Turgeon, President and CEO of Spectrum Pharmaceuticals. "We
22 believe the pre-approval inspection marks the final step in the ROLONTIS
23 review process."

24 47. On March 30, 2021, Spectrum issued a press release announcing the Company's Q4 and
25 full year 2020 financial results and pipeline update. The press release stated, in relevant part, "[. . .] we
26 are delighted that the FDA has scheduled the pre-approval inspection at the ROLONTIS manufacturing
27 facility for May 2021. The company has made tremendous progress advancing our development programs
28 and conducting our clinical trials, despite the challenges of the global pandemic. I am proud of our
employees who demonstrated resiliency and creativity during these unprecedented times."

48. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
the Company's Q4 and full year 2020 results (the "Q4 2020 Earnings Call"). During the scripted portion
of the Q4 2020 Earnings Call, Defendant Turgeon stated, in relevant part:

1 Regarding ROLONTIS, the FDA is scheduled to perform the pre-approval
2 inspection of our manufacturing facility in May. As you may recall, FDA
3 informed us last year that it was deferring action on the BLA due to their
4 inability to inspect the Hanmi Bioplant in South Korea as a result of travel
5 restrictions related to the COVID-19 pandemic.

6 Hanmi Pharmaceuticals is an experienced biopharmaceutical manufacturer
7 with a world-class facility, and they are ready for this inspection. As a
8 matter of fact, Hanmi has received recently approval for ROLONTIS in
9 Korea, which further raises our confidence in their manufacturing readiness.

10 ***

11 I think you can see from everyone's remarks that Spectrum continues to
12 make strong and steady progress on our pipeline. We look forward to the
13 completion of the inspection of our ROLONTIS manufacturing facility.

14 Also during the scripted portion of the Q4 2020 Earnings Call, Defendant Lebel stated, in relevant part:

15 Our BLA for ROLONTIS is supported by robust clinical data from two
16 large randomized clinical trials. Regarding the deferred action on our
17 ROLONTIS filing that Joe mentioned, we believe with that we have
18 answered satisfactorily all questions from the FDA related to the review of
19 the BLA, and we believe that the inspection represents the final step in the
20 review process. We and our partner Hanmi are ready for the FDA
21 preapproval planned inspection that has been scheduled for May.

22 Finally, when asked to provide clarity on the "specific next steps after the [ROLANTIS facility]
23 inspection," Defendant Lebel stated, in relevant part:

24 So let me start with -- let's just say that when we got the deferral as opposed
25 to a complete response CRL that usually indicates that the FDA is, they are
26 pausing their review and the only step left to our knowledge is the
27 inspection.

28 We have had a lot of discussion with the FDA on all the other matters, and
our understanding is that we have answered all their questions satisfactorily.
So, we believe the inspection is fundamentally the last step.

As to the timing following an inspection assuming that there's no issues,
roughly I think a little more than a month, probably[.]

1 49. On March 31, 2021, Spectrum filed an Annual Report on Form 10-K with the SEC,
2 reporting the Company’s financial and operating results for the year ended December 31, 2020 (the “2020
3 10-K”). The 2020 10-K listed as one of the recent highlights of the Company’s business:

4 **ROLONTIS, a novel long-acting G-CSF:**

5 We submitted our updated BLA for ROLONTIS to the FDA on October 24,
6 2019, which was accepted for review by the FDA on December 20, 2019.
7 Our BLA is supported by data from two similarly designed Phase 3 clinical
8 trials, ADVANCE and RECOVER, which evaluated the safety and efficacy
9 of ROLONTIS in 643 early-stage breast cancer patients for the treatment of
10 neutropenia due to myelosuppressive chemotherapy. On October 26, 2020,
11 we announced that the FDA PDUFA target action date set for October 24,
12 2020 was deferred pending inspection of the Hanmi manufacturing facility
13 in Korea due to COVID-19 related travel restrictions. In March 2021, the
14 FDA scheduled the pre-approval inspection of the Hanmi manufacturing
15 facility for May 2021.

16 50. Appended to the 2020 10-K as exhibits were signed certifications pursuant to SOX by
17 Defendants Turgeon and Gustafson, attesting that “the information contained in the [2020 10-K] fairly
18 presents, in all material respects, the financial condition and results of operations of the Company.”

19 51. On May 13, 2021, Spectrum issued a press release announcing the Company’s Q1 2021
20 financial results and corporate update. The press release stated, in relevant part, “[w]e also look forward
21 to the FDA’s pre-approval inspection of the ROLONTIS manufacturing facility which has been
22 scheduled for later this month,” and “[t]he FDA’s pre-approval inspection of the ROLONTIS
23 manufacturing facility has been scheduled for later this month and pre-commercial preparation activities
24 are underway.”

25 52. That same day, Spectrum hosted an earnings call with investors and analysts to discuss
26 the Company’s Q1 2021 results (the “Q1 2021 Earnings Call”). During the scripted portion of the Q1
27 2021 Earnings Call, Defendant Turgeon stated, in relevant part:

28 Now, regarding ROLONTIS, the FDA scheduled the pre-approval
inspection of our manufacturing facility for later this month. We believe
this inspection marks the final step in the approval process and that Hanmi’s

1 world class facility is ready for this inspection. We are making real progress
2 on our two lead clinical programs with major catalysts expected in the
3 coming months, including a launch and an NDA filing.

4 ***

5 Spectrum continues to make strong and steady progress on our development
6 pipeline. We look forward to the completion of the inspection of our
7 ROLONTIS manufacturing facility, which is planned to begin shortly.

8 Also during the scripted portion of the Q1 2021 Earnings Call, Defendant Lebel stated, in relevant part,
9 “[n]ow, let me shift to ROLONTIS. On the regulatory side, [Defendant Turgeon] has already updated
10 you on the status of the pre-approval inspection and we remain confident that our preparation with our
11 partner, Hanmi, should result in a positive outcome for this FDA plant inspection.” Further, when asked
12 about the next steps after the pre-approval inspection of the ROLONTIS manufacturing plant, Defendant
13 Turgeon responded, in relevant part, “[w]e’re prepared for the inspection. We’re looking forward to it. I
14 can’t give you an exact date, but I think the FDA would take a reasonable amount of time to get back to
15 us once the inspection is done and we feel that’s the last step. So without giving the exact time, I think
16 it’ll be a reasonable amount of time after the inspection is done.”

17 53. The statements referenced in ¶¶ 21-52 were materially false and misleading because
18 Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts
19 about the Company’s business, operations, and compliance policies. Specifically, Defendants made false
20 and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS manufacturing facility
21 maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood
22 that the FDA would approve the ROLONTIS BLA in its current form; (iii) Spectrum had therefore
23 materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, the Company’s
24 public statements were materially false and misleading at all relevant times.
25
26
27
28

The Truth Emerges

1
2 54. On August 6, 2021, Spectrum announced receipt of a CRL from the FDA regarding the
3 ROLONTIS BLA. Specifically, the press release stated:

4 The CRL cited deficiencies related to manufacturing and indicated that a
5 reinspection of the Company’s manufacturing facility will be necessary.
6 The company is seeking further clarification from the FDA and plans to
7 meet with the agency as soon as possible.

8 “We are disappointed with this outcome and look forward to fully
9 understanding the remediation timelines for the program,” said Joe
10 Turgeon, President and CEO of Spectrum Pharmaceuticals. “We continue
11 to believe in ROLONTIS and plan to diligently complete the regulatory
12 process to bring ROLONTIS to market.”

13 55. On this news, Spectrum’s stock price fell \$0.70 per share, or 21.54%, to close at \$2.55 per
14 share on August 6, 2021.

15 56. As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the
16 market value of the Company’s securities, Plaintiff and other Class members have suffered significant
17 losses and damages.

PLAINTIFF’S CLASS ACTION ALLEGATIONS

18 57. Plaintiff brings this action as a class action pursuant to Federal Rule of Civil Procedure
19 23(a) and (b)(3) on behalf of a Class, consisting of all those who purchased or otherwise acquired
20 Spectrum securities during the Class Period (the “Class”); and were damaged upon the revelation of the
21 alleged corrective disclosures. Excluded from the Class are Defendants herein, the officers and directors
22 of the Company, at all relevant times, members of their immediate families and their legal representatives,
23 heirs, successors or assigns and any entity in which Defendants have or had a controlling interest.

24 58. The members of the Class are so numerous that joinder of all members is impracticable.
25 Throughout the Class Period, Spectrum securities were actively traded on the NASDAQ. While the exact
26 number of Class members is unknown to Plaintiff at this time and can be ascertained only through
27
28

1 appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed
2 Class. Record owners and other members of the Class may be identified from records maintained by
3 Spectrum or its transfer agent and may be notified of the pendency of this action by mail, using the form
4 of notice similar to that customarily used in securities class actions.

5 59. Plaintiff's claims are typical of the claims of the members of the Class as all members of
6 the Class are similarly affected by Defendants' wrongful conduct in violation of federal law that is
7 complained of herein.
8

9 60. Plaintiff will fairly and adequately protect the interests of the members of the Class and
10 has retained counsel competent and experienced in class and securities litigation. Plaintiff has no interests
11 antagonistic to or in conflict with those of the Class.
12

13 61. Common questions of law and fact exist as to all members of the Class and predominate
14 over any questions solely affecting individual members of the Class. Among the questions of law and
15 fact common to the Class are:

- 16 • whether the federal securities laws were violated by Defendants' acts as alleged herein;
- 17 • whether statements made by Defendants to the investing public during the Class Period
18 misrepresented material facts about the business, operations and management of
19 Spectrum;
- 20 • whether the Individual Defendants caused Spectrum to issue false and misleading
21 financial statements during the Class Period;
- 22 • whether Defendants acted knowingly or recklessly in issuing false and misleading
23 financial statements;
- 24 • whether the prices of Spectrum securities during the Class Period were artificially inflated
because of the Defendants' conduct complained of herein; and
- 25 • whether the members of the Class have sustained damages and, if so, what is the proper
26 measure of damages.

1 62. A class action is superior to all other available methods for the fair and efficient
2 adjudication of this controversy since joinder of all members is impracticable. Furthermore, as the
3 damages suffered by individual Class members may be relatively small, the expense and burden of
4 individual litigation make it impossible for members of the Class to individually redress the wrongs done
5 to them. There will be no difficulty in the management of this action as a class action.

6 63. Plaintiff will rely, in part, upon the presumption of reliance established by the fraud-on-
7 the-market doctrine in that:
8

- 9 • Defendants made public misrepresentations or failed to disclose material facts during the
10 Class Period;
- 11 • the omissions and misrepresentations were material;
- 12 • Spectrum securities are traded in an efficient market;
- 13 • the Company's shares were liquid and traded with moderate to heavy volume during the
14 Class Period;
- 15 • the Company traded on the NASDAQ and was covered by multiple analysts;
- 16 • the misrepresentations and omissions alleged would tend to induce a reasonable investor
17 to misjudge the value of the Company's securities; and
- 18 • Plaintiff and members of the Class purchased, acquired and/or sold Spectrum securities
19 between the time the Defendants failed to disclose or misrepresented material facts and
20 the time the true facts were disclosed, without knowledge of the omitted or misrepresented
21 facts.

22 64. Based upon the foregoing, Plaintiff and the members of the Class are entitled to a
23 presumption of reliance upon the integrity of the market.

24 65. Alternatively, Plaintiff and the members of the Class are entitled to the presumption of
25 reliance established by the Supreme Court in *Affiliated Ute Citizens of the State of Utah v. United States*,
26 406 U.S. 128, 92 S. Ct. 2430 (1972), as Defendants omitted material information in their Class Period
27 statements in violation of a duty to disclose such information, as detailed above.
28

FIRST CLAIM FOR RELIEF

(Violations of Section 10(b) of the Exchange Act and Rule 10b-5 Promulgated Thereunder Against All Defendants)

66. Plaintiff repeats and re-alleges each and every allegation contained above as if fully set forth herein.

67. This Count is asserted against Defendants and is based upon Section 10(b) of the Exchange Act, 15 U.S.C. § 78j(b), and Rule 10b-5 promulgated thereunder by the SEC.

68. During the Class Period, Defendants engaged in a plan, scheme, conspiracy and course of conduct, pursuant to which they knowingly or recklessly engaged in acts, transactions, practices and courses of business which operated as a fraud and deceit upon Plaintiff and the other members of the Class; made various untrue statements of material facts and omitted to state material facts necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading; and employed devices, schemes and artifices to defraud in connection with the purchase and sale of securities. Such scheme was intended to, and, throughout the Class Period, did: (i) deceive the investing public, including Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Spectrum securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Spectrum securities and options at artificially inflated prices. In furtherance of this unlawful scheme, plan and course of conduct, Defendants, and each of them, took the actions set forth herein.

69. Pursuant to the above plan, scheme, conspiracy and course of conduct, each of the Defendants participated directly or indirectly in the preparation and/or issuance of the quarterly and annual reports, SEC filings, press releases and other statements and documents described above, including statements made to securities analysts and the media that were designed to influence the market for Spectrum securities. Such reports, filings, releases and statements were materially false and

1 misleading in that they failed to disclose material adverse information and misrepresented the truth about
2 Spectrum's finances and business prospects.

3 70. By virtue of their positions at Spectrum, Defendants had actual knowledge of the
4 materially false and misleading statements and material omissions alleged herein and intended thereby to
5 deceive Plaintiff and the other members of the Class, or, in the alternative, Defendants acted with reckless
6 disregard for the truth in that they failed or refused to ascertain and disclose such facts as would reveal
7 the materially false and misleading nature of the statements made, although such facts were readily
8 available to Defendants. Said acts and omissions of Defendants were committed willfully or with reckless
9 disregard for the truth. In addition, each Defendant knew or recklessly disregarded that material facts
10 were being misrepresented or omitted as described above.
11

12 71. Information showing that Defendants acted knowingly or with reckless disregard for the
13 truth is peculiarly within Defendants' knowledge and control. As the senior managers and/or directors
14 of Spectrum, the Individual Defendants had knowledge of the details of Spectrum's internal affairs.
15

16 72. The Individual Defendants are liable both directly and indirectly for the wrongs
17 complained of herein. Because of their positions of control and authority, the Individual Defendants were
18 able to and did, directly or indirectly, control the content of the statements of Spectrum. As officers
19 and/or directors of a publicly-held company, the Individual Defendants had a duty to disseminate timely,
20 accurate, and truthful information with respect to Spectrum's businesses, operations, future financial
21 condition and future prospects. As a result of the dissemination of the aforementioned false and
22 misleading reports, releases and public statements, the market price of Spectrum securities was artificially
23 inflated throughout the Class Period. In ignorance of the adverse facts concerning Spectrum's business
24 and financial condition which were concealed by Defendants, Plaintiff and the other members of the Class
25 purchased or otherwise acquired Spectrum securities at artificially inflated prices and relied upon the
26
27
28

1 price of the securities, the integrity of the market for the securities and/or upon statements disseminated
2 by Defendants, and were damaged thereby.

3 73. During the Class Period, Spectrum securities were traded on an active and efficient
4 market. Plaintiff and the other members of the Class, relying on the materially false and misleading
5 statements described herein, which the Defendants made, issued or caused to be disseminated, or relying
6 upon the integrity of the market, purchased or otherwise acquired shares of Spectrum securities at prices
7 artificially inflated by Defendants' wrongful conduct. Had Plaintiff and the other members of the Class
8 known the truth, they would not have purchased or otherwise acquired said securities, or would not have
9 purchased or otherwise acquired them at the inflated prices that were paid. At the time of the purchases
10 and/or acquisitions by Plaintiff and the Class, the true value of Spectrum securities was substantially
11 lower than the prices paid by Plaintiff and the other members of the Class. The market price of Spectrum
12 securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and
13 Class members.
14

15
16 74. By reason of the conduct alleged herein, Defendants knowingly or recklessly, directly or
17 indirectly, have violated Section 10(b) of the Exchange Act and Rule 10b-5 promulgated thereunder.
18

19 75. As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and the other
20 members of the Class suffered damages in connection with their respective purchases, acquisitions and
21 sales of the Company's securities during the Class Period, upon the disclosure that the Company had
22 been disseminating misrepresented financial statements to the investing public.
23

24 **SECOND CLAIM FOR RELIEF**

25 **(Violations of Section 20(a) of the Exchange Act Against the Individual Defendants)**

26 76. Plaintiff repeats and re-alleges each and every allegation contained in the foregoing
27 paragraphs as if fully set forth herein.
28

1 77. During the Class Period, the Individual Defendants participated in the operation and
2 management of Spectrum, and conducted and participated, directly and indirectly, in the conduct of
3 Spectrum's business affairs. Because of their senior positions, they knew the adverse non-public
4 information about Spectrum's misstatement of income and expenses and false financial statements.

5 78. As officers and/or directors of a publicly owned company, the Individual Defendants had
6 a duty to disseminate accurate and truthful information with respect to Spectrum's financial condition
7 and results of operations, and to correct promptly any public statements issued by Spectrum which had
8 become materially false or misleading.

9 79. Because of their positions of control and authority as senior officers, the Individual
10 Defendants were able to, and did, control the contents of the various reports, press releases and public
11 filings which Spectrum disseminated in the marketplace during the Class Period concerning Spectrum's
12 results of operations. Throughout the Class Period, the Individual Defendants exercised their power and
13 authority to cause Spectrum to engage in the wrongful acts complained of herein. The Individual
14 Defendants, therefore, were "controlling persons" of Spectrum within the meaning of Section 20(a) of
15 the Exchange Act. In this capacity, they participated in the unlawful conduct alleged which artificially
16 inflated the market price of Spectrum securities.

17 80. Each of the Individual Defendants, therefore, acted as a controlling person of Spectrum.
18 By reason of their senior management positions and/or being directors of Spectrum, each of the Individual
19 Defendants had the power to direct the actions of, and exercised the same to cause, Spectrum to engage
20 in the unlawful acts and conduct complained of herein. Each of the Individual Defendants exercised
21 control over the general operations of Spectrum and possessed the power to control the specific activities
22 which comprise the primary violations about which Plaintiff and the other members of the Class
23 complain.
24
25
26
27
28

